Wave Life Sciences (WVE) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

INLIGHT Phase 1 data continue to support WVE-007's novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen…

CAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, toda…

Wave Life Sciences, Inc. remains a 'Hold,' as I see limited near-term upside amid competitive obesity and AATD markets. WVE-007's modest ~1% weight loss at six months lags GLP-1 peers, though muscle preservation and dosi…

Wave aligned with the FDA on a single trial for WVE-006. Cash and marketable securities reached $431 million to fund operations into 2028.…

Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript…

WAVE Life Sciences NASDAQ: WVE used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing up…

Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript…

WAVE Life Sciences NASDAQ: WVE reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease.…

Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.32 per share a year ago.…

Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers…

WAVE Life Sciences NASDAQ: WVE outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the company's chemistry platfo…

CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will…

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, anno…

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, toda…

WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report)'s share price reached a new 52-week low during trading on Monday. The company traded as low as $3.37 and last traded at $3.3850, with a volume of 317,423 shares tra…

WAVE Life Sciences (NASDAQ: WVE - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies ba…

Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) rose 9.3% on Thursday. The company traded as high as $4.02 and last traded at $4.0440. 544,448 shares were traded during mid-day trading, a decline of 86%…

Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $3.64, but opened at $3.79. WAVE Life Sciences shares last traded at $…

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers…

Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing…

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.…

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 a…

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.…

Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

